The Association Between ICD Interventions and Mortality is Independent of their Modality: Clinical Implications

被引:17
作者
Bencardino, Gianluigi [1 ]
Di Monaco, Antonio [1 ]
Rio, Teresa [1 ]
Frontera, Antonio [1 ]
Santangeli, Pasquale [2 ]
Leo, Milena [1 ]
Pelargonio, Gemma [1 ]
Perna, Francesco [1 ]
Narducci, Maria Lucia [1 ]
Gabrielli, Francesca [1 ]
Lanza, Gaetano Antonio [1 ]
Bellocci, Fulvio [1 ]
Rebuzzi, Antonio [1 ]
Crea, Filippo [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Dept Cardiovasc Med, I-00168 Rome, Italy
[2] St Davids Med Ctr, Texas Cardiac Arrhythmia Inst, Austin, TX USA
关键词
antitachycardia pacing; heart failure; ICD shock; implantable cardioverter-defibrillator; mortality; ventricular arrhythmias; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; HEART-FAILURE PATIENTS; PROPHYLACTIC IMPLANTATION; SHOCKS; THERAPY; TRIAL; RISK; TERM; PREVENTION; DISEASE;
D O I
10.1111/jce.12499
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ICD Interventions and Mortality. Background: Patients with severe structural heart disease have increased mortality after implantable cardioverter-defibrillator (ICD) shocks. Whether this is limited to ICD shock therapy only or extends also to no-shock therapies, such as antitachycardia pacing (ATP), is unclear. We investigated the impact of different ICD therapies on long-term mortality. Methods: We enrolled 573 patients who underwent ICD implantation at our institution from 2004 to 2011. The population was divided into 3 groups: no device interventions (group 1), ATP interventions (group 2), and shock interventions (group 3). The endpoint was the all-cause mortality. Results: Over a follow-up period of 48 months (range 1-110), 447 (78%) had no device interventions, 71 (12%) had ATP therapy only, and 55 (10%) had at least one shock intervention. All-cause mortality occurred in 94 patients in group 1 (21%), 23 patients (43%) in group 2, and 21 patients (38%) in group 3. At multivariable Cox regression analysis, ATP intervention (HR: 1.8; 95% CI 1.1-3; P < 0.001), shock intervention (HR: 1.39; 95% CI 1.09-1.77; P = 0.008), age (HR: 1.05; 95% CI 1.02-1.07; P < 0.001), and LVEF (HR: 0.95; 95% CI 0.93-0.98; P = 0.001) were predictors of all-cause mortality. No significant difference in mortality was found between group 2 and 3. Conclusion: Patients with ICDs who receive appropriate interventions are at increased risk of mortality. Such risk is not dependent on different types of ICD therapy, such as shocks or ATP. Our data suggest that sustained ventricular arrhythmias per se have a negative impact on prognosis rather than modality of ICD therapy.
引用
收藏
页码:1363 / 1367
页数:5
相关论文
共 22 条
  • [1] Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure
    Bardy, GH
    Lee, KL
    Mark, DB
    Poole, JE
    Packer, DL
    Boineau, R
    Domanski, M
    Troutman, C
    Anderson, J
    Johnson, G
    McNulty, SE
    Clapp-Channing, N
    Davidson-Ray, LD
    Fraulo, ES
    Fishbein, DP
    Luceri, RM
    Ip, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) : 225 - 237
  • [2] A randomized study of the prevention of sudden death in patients with coronary artery disease
    Buxton, AE
    Lee, KL
    Fisher, JD
    Josephson, ME
    Prystowsky, EN
    Hafley, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (25) : 1882 - 1890
  • [3] Device Therapy in Heart Failure Patients With Chronic Kidney Disease
    Cannizzaro, Leon A.
    Piccini, Jonathan P.
    Patel, Uptal D.
    Hernandez, Adrian F.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (09) : 889 - 896
  • [4] Catheter ablation for the treatment of electrical storm in patients with Implantable cardioverter-defibrillators - Short- and long-term outcomes in a prospective single-center study
    Carbucicchio, Corrado
    Santamaria, Matteo
    Trevisi, Nicola
    Maccabelli, Giuseppe
    Giraldi, Francesco
    Fassini, Gaetano
    Riva, Stefania
    Moltrasio, Massimo
    Cireddu, Manuela
    Veglia, Fabrizio
    Della Bella, Paolo
    [J]. CIRCULATION, 2008, 117 (04) : 462 - 469
  • [5] Canadian implantable defibrillator study (CIDS) - A randomized trial of the implantable cardioverter defibrillator against amiodarone
    Connolly, SJ
    Gent, M
    Roberts, RS
    Dorian, P
    Roy, D
    Sheldon, RS
    Mitchell, LB
    Green, MS
    Klein, GJ
    O'Brien, B
    [J]. CIRCULATION, 2000, 101 (11) : 1297 - 1302
  • [6] Inappropriate implantable cardioverter-defibrillator shocks in MADIT II
    Daubert, James P.
    Zareba, Wojciech
    Cannom, David S.
    McNitt, Scott
    Rosero, Spencer Z.
    Wang, Paul
    Schuger, Claudio
    Steinberg, Jonathan S.
    Higgins, Steven L.
    Wilber, David J.
    Klein, Helmut
    Andrews, Mark L.
    Hall, W. Jackson
    Moss, Arthur J.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (14) : 1357 - 1365
  • [7] 2010 Focused Update of ESC Guidelines on device therapy in heart failure
    Dickstein, Kenneth
    Vardas, Panos E.
    Auricchio, Angelo
    Daubert, Jean-Claude
    Linde, Cecilia
    McMurray, John
    Ponikowski, Piotr
    Priori, Silvia Giuliana
    Sutton, Richard
    van Veldhuisen, Dirk J.
    [J]. EUROPACE, 2010, 12 (11): : 1526 - 1536
  • [8] Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II
    Goldenberg, I
    Moss, AJ
    Hall, J
    McNitt, S
    Zareba, W
    Andrews, ML
    Cannom, DS
    [J]. CIRCULATION, 2006, 113 (24) : 2810 - 2817
  • [9] Prevention of sudden cardiac death in patients with chronic kidney disease: risk and benefits of the implantable cardioverter defibrillator
    Hoffmeister, Jana M.
    Estes, N. A. Mark, III
    Garlitski, Ann C.
    [J]. JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2012, 35 (02) : 227 - 234
  • [10] Relation of advanced heart failure symptoms to risk of inappropriate defibrillator shocks
    Hreybe, H
    Ezzeddine, R
    Barrington, W
    Bazaz, R
    Jain, S
    Ngwu, O
    Saba, S
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (04) : 544 - 546